Abstract
It has been reported that DOK3 protein negatively regulates LPS responses and endotoxin tolerance in mice. However, the role of DOK3 in the development of acute respiratory distress syndrome (ARDS) remains unknown. In this study, we showed that DOK3 is degraded in the lung tissues of LPS-induced ARDS. Through lentivirus transduction containing DOK3(K27R) via the intranasal route, we created a mice model, in which DOK3 maintains stable expression. We found that the forced DOK3 expression significantly attenuated LPS-induced pulmonary histological alterations, inflammatory cells infiltration, lung edema, as well as the generation of inflammatory cytokines TNFα, IL- 1β and IL-6 in BALF of LPS-induced ARDS mice. In addition, DOK3 expression apparently suppressed LPS-induced NF-κB and ERK activation. These data suggested that DOK3 expression negatively regulates the development of LPS-induced ARDS in mice.
Keywords: ARDS, DOK3, Lentivirus, LPS, Degradation, Expression.
Current Gene Therapy
Title:DOK3 Degradation is Required for the Development of LPS-induced ARDS in Mice
Volume: 16 Issue: 4
Author(s): Ning Liu, Xiaofeng Liu, Xiaoou Li, Kaifang Duan, Yuming Deng, Xiuyan Yu and Qisheng Peng
Affiliation:
Keywords: ARDS, DOK3, Lentivirus, LPS, Degradation, Expression.
Abstract: It has been reported that DOK3 protein negatively regulates LPS responses and endotoxin tolerance in mice. However, the role of DOK3 in the development of acute respiratory distress syndrome (ARDS) remains unknown. In this study, we showed that DOK3 is degraded in the lung tissues of LPS-induced ARDS. Through lentivirus transduction containing DOK3(K27R) via the intranasal route, we created a mice model, in which DOK3 maintains stable expression. We found that the forced DOK3 expression significantly attenuated LPS-induced pulmonary histological alterations, inflammatory cells infiltration, lung edema, as well as the generation of inflammatory cytokines TNFα, IL- 1β and IL-6 in BALF of LPS-induced ARDS mice. In addition, DOK3 expression apparently suppressed LPS-induced NF-κB and ERK activation. These data suggested that DOK3 expression negatively regulates the development of LPS-induced ARDS in mice.
Export Options
About this article
Cite this article as:
Liu Ning, Liu Xiaofeng, Li Xiaoou, Duan Kaifang, Deng Yuming, Yu Xiuyan and Peng Qisheng, DOK3 Degradation is Required for the Development of LPS-induced ARDS in Mice, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161103142342
DOI https://dx.doi.org/10.2174/1566523216666161103142342 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Current Medicinal Chemistry Cardiovascular Effects of Green Tea Catechins: Progress and Promise
Recent Patents on Cardiovascular Drug Discovery Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Adiponectin and its Receptors as Potential Therapeutical Targets
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Use of Lectins as Tools to Combat SARS-CoV-2
Current Pharmaceutical Design Current Screens Based on the AlphaScreen™ Technology for Deciphering Cell Signalling Pathways
Current Genomics Fibromyalgia: Mechanisms, Current Treatment and Animal Models
Current Pharmaceutical Biotechnology Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist
Current Immunology Reviews (Discontinued) Recent Knowledge and Insights on the Mechanisms of Immediate Hypersensitivity and Anaphylaxis: IgE/FcεRI- and Non-IgE/FcεRI-Dependent Anaphylaxis
Current Pharmaceutical Design Bone Tissue Regeneration - Application of Mesenchymal Stem Cells and Cellular and Molecular Mechanisms
Current Stem Cell Research & Therapy NMR Screening and Hit Validation in Fragment Based Drug Discovery
Current Topics in Medicinal Chemistry Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens
Current Cancer Drug Targets Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Chemical Constituents and Biological Activities of Vietnamese Medicinal Plants
Current Topics in Medicinal Chemistry